Chaofu Li

Chaofu Li

Auto-generated profile, based on publicly available information

Chaofu Li

Bioengineering College of Chongqing University Chongqing University Central Hospital (Chongqing Emergency Medical Center) Chongqing China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2023 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
YZYongchao Zhao
Yongchao Zhao
WXWeidong Xiong
Weidong Xiong
CLChaofu Li
Chaofu Li
RZRanzun Zhao
Ranzun Zhao
YDYuxiang Dai
Yuxiang Dai
JGJunbo Ge
Junbo Ge
Hypoxia, characterized by reduced oxygen concentration, is a significant stressor that affects the survival of aerobic species and plays a prominent role in cardiovascular diseases. From the research history and milestone events related to hypoxia in cardiovascular development and diseases, The "hypoxia-inducible factors (HIFs) switch" can be observed from both temporal and spatial perspectives, encompassing the occurrence and progression of hypoxia (gradual decline in oxygen concentration), the acute and chronic manifestations of hypoxia, and the geographical characteristics of hypoxia (natural selection at high altitudes). Furthermore, hypoxia signaling pathways are associated with natural rhythms, such as diurnal and hibernation processes. In addition to innate factors and natural selection, it has been found that epigenetics, as a postnatal factor, profoundly influences the hypoxic response and progression within the cardiovascular system. Within this intricate process, interactions between different tissues and organs within the cardiovascular system and other systems in the context of hypoxia signaling pathways have been established. Thus, it is the time to summarize and to construct a multi-level regulatory framework of hypoxia signaling and mechanisms in cardiovascular diseases for developing more therapeutic targets and make reasonable advancements in clinical research, including FDA-approved drugs and ongoing clinical trials, to guide future clinical practice in the field of hypoxia signaling in cardiovascular diseases.

14 December 2025 in Medcomm
Verified
Journal Article
Open access
CLChaofu Li
Chaofu Li
YYYukun Yang
Yukun Yang
FZFating Zhou
Fating Zhou
QJQiuyan Jiang
Qiuyan Jiang
YJYingying Jiang
Yingying Jiang
CLChuanwei Li
Chuanwei Li
Efferocytosis is the fundamental mechanism by which phagocytes clear apoptotic cells to maintain tissue homeostasis. This process is also closely linked to immune tolerance, metabolic reprogramming, inflammation resolution, and tissue repair. In recent years, research spanning cardiovascular disease, autoimmune disorders, metabolic inflammation, neurodegeneration, and cancer has revealed diverse context‐dependent regulatory networks, including “eat‐me” and “don't‐eat‐me” signals, phagocytic receptors, intracellular signaling pathways, and metabolic checkpoints. Disruption of these regulatory layers contributes to the defective resolution of inflammation, persistent immune activation, and impaired tissue regeneration. However, a unified comparative framework that integrates these mechanisms across different disease states is lacking. In this review, we provide a comprehensive overview of the biology of efferocytosis, from apoptotic cell recognition and engulfment to downstream immunometabolic rewiring. We highlight disease‐specific alterations in atherosclerosis, myocardial infarction, autoimmune diseases, neuroinflammation, and the tumor microenvironment. In addition, we summarize the emerging therapeutic strategies, including receptor agonists, metabolic interventions, engineered extracellular vesicles, and immune checkpoint modulation. Finally, we propose a “full‐cycle” monitoring strategy that integrates imaging‐based quantification, circulating biomarkers, multiomics profiling, and artificial intelligence to enable dynamic assessment of efferocytosis in vivo.

20 April 2022 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
XLXianping Long
Xianping Long
ZQZhimei Qiu
Zhimei Qiu
CLChaofu Li
Chaofu Li
YWYan Wang
Yan Wang
JLJiao Li
Jiao Li
BSBei Shi
Bei Shi
Myocardial infarction is one of the leading diseases causing death and disability worldwide, and the revascularization of damaged tissues is essential for myocardial-injury repair. Circular RNAs (circRNAs) are widely involved in physiological and pathological processes in various systems throughout the body, and the role of circRNAs in cardiovascular disease is gaining attention. In this study, we determined that circERBB2IP is highly expressed in the hearts of newborn mice. Silencing or overexpression of circERBB2IP inhibited and promoted angiogenesis in vivo and in vitro, respectively. Mechanistically, the transcription factor GATA4 promotes the production of circERBB2IP. Furthermore, circERBB2IP functioned as an endogenous miR-145a-5p sponge and was able to sequester and repress miR-145a-5p activity, which led to an increased expression level of Smad5. In summary, circERBB2IP can promote angiogenesis after myocardial infarction through the miR-145a-5p/Smad5 axis. These data suggest that circERBB2IP may be a potential therapeutic target for the treatment of myocardial infarction.

13 June 2023 in Advanced Science
Verified
Journal Article
Open access
CLChaofu Li
Chaofu Li
YZYongchao Zhao
Yongchao Zhao
FLFuhai Li
Fuhai Li
ZWZimu Wang
Zimu Wang
ZQZhimei Qiu
Zhimei Qiu
JGJunbo Ge
Junbo Ge
Microvascular endothelial cells (MiVECs) impair angiogenic potential, leading to microvascular rarefaction, which is a characteristic feature of chronic pressure overload‐induced cardiac dysfunction. Semaphorin3A (Sema3A) is a secreted protein upregulated in MiVECs following angiotensin II (Ang II) activation and pressure overload stimuli. However, its role and mechanism in microvascular rarefaction remain elusive. The function and mechanism of action of Sema3A in pressure overload‐induced microvascular rarefaction, is explored, through an Ang II‐induced animal model of pressure overload. RNA sequencing, immunoblotting analysis, enzyme‐linked immunosorbent assay, quantitative reverse transcription polymerase chain reaction (qRT‐PCR), and immunofluorescence staining results indicate that Sema3A is predominantly expressed and significantly upregulated in MiVECs under pressure overload. Immunoelectron microscopy and nano‐flow cytometry analyses indicate small extracellular vesicles (sEVs), with surface‐attached Sema3A, to be a novel tool for efficient release and delivery of Sema3A from the MiVECs to extracellular microenvironment. To investigate pressure overload‐mediated cardiac microvascular rarefaction and cardiac fibrosis in vivo, endothelial‐specific Sema3A knockdown mice are established. Mechanistically, serum response factor (transcription factor) promotes the production of Sema3A; Sema3A‐positive sEVs compete with vascular endothelial growth factor A to bind to neuropilin‐1. Therefore, MiVECs lose their ability to respond to angiogenesis. In conclusion, Sema3A is a key pathogenic mediator that impairs the angiogenic potential of MiVECs, which leads to cardiac microvascular rarefaction in pressure overload‐induced heart disease.

1 November 2024 in Life Sciences
Verified
Journal Article
Closed access
FPFengli Peng
Fengli Peng
ZWZimu Wang
Zimu Wang
ZQZhimei Qiu
Zhimei Qiu
WZWei Zhang
Wei Zhang
YZYongchao Zhao
Yongchao Zhao
BSBei Shi
Bei Shi

2 July 2025 in Theranostics
Verified
Journal Article
Open access
PDF file
FPFengli Peng
Fengli Peng
ZQZhimei Qiu
Zhimei Qiu
ZWZimu Wang
Zimu Wang
FLFuhai Li
Fuhai Li
FZFating Zhou
Fating Zhou
BSBei Shi
Bei Shi
MRNA serves as a versatile platform for the expression of paracrine factors, thereby promoting cardioprotection and regeneration. In recent years, mRNA and gene editing technologies have emerged as innovative tools for tackling complex diseases. Among these, mRNA therapeutics offer distinct advantages, including favorable immunological properties, strong safety profiles, and superior flexibility compared to conventional gene-based vaccines. Specifically, they can elicit a balanced immune response—encompassing both cellular and humoral immunity—without being limited by MHC haplotypes. Furthermore, mRNA therapy represents a particularly safe treatment modality. As a minimal and transient carrier of genetic information that does not integrate into the host genome, it significantly reduces the risk of insertional mutagenesis. Importantly, mRNA can be used to express virtually any protein without requiring changes to the production process, thus offering substantial flexibility in drug development. Collectively, these attributes highlight the great potential of mRNA as a next-generation therapeutic platform, particularly for cardiovascular diseases. This review summarizes recent progress in the development and application of mRNA-based drug formulations for cardiovascular therapy.